PHI’s acting CEO: ”We aim to drive innovation that accelerates breakthroughs in regenerative medicine”
With the introduction of the HoloMonitor CellSync, Phase Holographic Imaging (PHI) leaps forward in live cell imaging technology. Currently in the final stages of development, this next-generation imaging system is undergoing pre-production testing at prestigious U.S. institutions – the Huntsman Cancer Institute and the Wake Forest Institute of Regenerative Medicine. We spoke with the acting CEO, Ivan Jurković, to learn more.
Read the full interview with Ivan Jurković at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/